 Yuwen Zhu
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, G-Protein-Coupled | 4 | 2026 | 233 | 2.740 |
Why?
| | Neoplasms | 11 | 2025 | 2875 | 1.930 |
Why?
| | Membrane Glycoproteins | 4 | 2026 | 496 | 1.710 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1982 | 1.510 |
Why?
| | Tumor Microenvironment | 8 | 2025 | 732 | 1.320 |
Why?
| | Pancreatic Neoplasms | 4 | 2025 | 919 | 1.190 |
Why?
| | Immunotherapy | 6 | 2024 | 653 | 1.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 154 | 0.960 |
Why?
| | Receptors, Lipoprotein | 1 | 2026 | 16 | 0.950 |
Why?
| | Intestinal Absorption | 1 | 2026 | 103 | 0.910 |
Why?
| | Receptors, Cell Surface | 2 | 2017 | 377 | 0.840 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 108 | 0.830 |
Why?
| | Lectins, C-Type | 1 | 2024 | 62 | 0.820 |
Why?
| | Lymphocyte Activation | 6 | 2016 | 1126 | 0.820 |
Why?
| | Dietary Fats | 1 | 2026 | 314 | 0.820 |
Why?
| | Neuroendocrine Tumors | 1 | 2025 | 112 | 0.810 |
Why?
| | Signal Transduction | 13 | 2026 | 5226 | 0.790 |
Why?
| | Immunity | 2 | 2021 | 139 | 0.790 |
Why?
| | CD28 Antigens | 3 | 2013 | 58 | 0.760 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2013 | 23 | 0.730 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.720 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.710 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.710 |
Why?
| | Melanoma | 2 | 2022 | 761 | 0.690 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 432 | 0.680 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 337 | 0.670 |
Why?
| | Immunomodulation | 2 | 2018 | 101 | 0.620 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 881 | 0.610 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.600 |
Why?
| | Animals | 26 | 2026 | 38058 | 0.590 |
Why?
| | Mice | 18 | 2026 | 18339 | 0.590 |
Why?
| | Killer Cells, Natural | 2 | 2023 | 467 | 0.560 |
Why?
| | Immunologic Factors | 2 | 2018 | 255 | 0.560 |
Why?
| | Thalidomide | 1 | 2018 | 43 | 0.560 |
Why?
| | Trastuzumab | 1 | 2017 | 118 | 0.490 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2016 | 5 | 0.480 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 241 | 0.480 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 206 | 0.470 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3540 | 0.470 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2016 | 42 | 0.470 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2016 | 24 | 0.470 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2022 | 291 | 0.470 |
Why?
| | Adenocarcinoma | 3 | 2022 | 928 | 0.470 |
Why?
| | Immunoglobulins | 2 | 2023 | 160 | 0.460 |
Why?
| | Ligands | 7 | 2023 | 673 | 0.460 |
Why?
| | Mice, Knockout | 6 | 2026 | 3121 | 0.440 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 199 | 0.430 |
Why?
| | Cell Adhesion Molecules | 1 | 2016 | 178 | 0.430 |
Why?
| | Antibodies, Monoclonal | 5 | 2025 | 1519 | 0.420 |
Why?
| | Skin Neoplasms | 1 | 2022 | 847 | 0.420 |
Why?
| | Central Nervous System | 1 | 2016 | 281 | 0.400 |
Why?
| | Endothelial Cells | 3 | 2026 | 869 | 0.390 |
Why?
| | Obesity | 1 | 2026 | 3077 | 0.370 |
Why?
| | Pancreas | 1 | 2014 | 341 | 0.360 |
Why?
| | Models, Immunological | 1 | 2011 | 100 | 0.330 |
Why?
| | Humans | 26 | 2026 | 144759 | 0.320 |
Why?
| | HEK293 Cells | 3 | 2021 | 744 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1455 | 0.280 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1313 | 0.260 |
Why?
| | Cell Movement | 2 | 2022 | 965 | 0.260 |
Why?
| | Cell Membrane | 1 | 2011 | 706 | 0.260 |
Why?
| | Ovarian Neoplasms | 1 | 2013 | 586 | 0.260 |
Why?
| | Mice, Inbred C57BL | 6 | 2026 | 5992 | 0.250 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 2194 | 0.250 |
Why?
| | Chylomicrons | 1 | 2026 | 19 | 0.240 |
Why?
| | Membrane Proteins | 1 | 2013 | 1166 | 0.240 |
Why?
| | Antigens, CD | 2 | 2024 | 555 | 0.230 |
Why?
| | Nephrotic Syndrome | 1 | 2026 | 44 | 0.230 |
Why?
| | Lipoproteins, HDL | 1 | 2026 | 101 | 0.230 |
Why?
| | Immunologic Memory | 2 | 2010 | 366 | 0.230 |
Why?
| | Podocytes | 1 | 2026 | 80 | 0.220 |
Why?
| | Intestine, Small | 1 | 2026 | 166 | 0.220 |
Why?
| | Inflammation | 1 | 2016 | 2878 | 0.210 |
Why?
| | Breast Neoplasms | 1 | 2017 | 2452 | 0.210 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2182 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 237 | 0.200 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 271 | 0.180 |
Why?
| | Neovascularization, Pathologic | 1 | 2024 | 286 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 928 | 0.180 |
Why?
| | Chemokines | 1 | 2022 | 218 | 0.170 |
Why?
| | Protein Binding | 2 | 2022 | 2273 | 0.170 |
Why?
| | Recombinant Fusion Proteins | 2 | 2016 | 675 | 0.170 |
Why?
| | Neuropeptides | 1 | 2021 | 77 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2022 | 177 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 917 | 0.170 |
Why?
| | Carcinogenesis | 1 | 2022 | 229 | 0.160 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.160 |
Why?
| | Tumor Burden | 1 | 2022 | 319 | 0.160 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2155 | 0.160 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1253 | 0.160 |
Why?
| | Survival Analysis | 2 | 2022 | 1382 | 0.150 |
Why?
| | Molecular Sequence Data | 2 | 2016 | 2930 | 0.150 |
Why?
| | Dendritic Cells | 2 | 2016 | 499 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2016 | 668 | 0.150 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 2016 | 100 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2020 | 259 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 223 | 0.140 |
Why?
| | MCF-7 Cells | 1 | 2017 | 135 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4557 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 415 | 0.120 |
Why?
| | Nectins | 1 | 2016 | 7 | 0.120 |
Why?
| | Cell Proliferation | 2 | 2021 | 2496 | 0.110 |
Why?
| | Receptors, Virus | 1 | 2016 | 96 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 99 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 396 | 0.110 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 155 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 200 | 0.110 |
Why?
| | Receptors, Complement | 2 | 2026 | 125 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2020 | 780 | 0.100 |
Why?
| | Vanadates | 1 | 2013 | 17 | 0.100 |
Why?
| | Succinimides | 1 | 2013 | 21 | 0.100 |
Why?
| | Phosphotyrosine | 1 | 2013 | 39 | 0.100 |
Why?
| | Fluoresceins | 1 | 2013 | 48 | 0.100 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 919 | 0.100 |
Why?
| | Models, Molecular | 2 | 2016 | 1618 | 0.100 |
Why?
| | B7 Antigens | 1 | 2013 | 18 | 0.090 |
Why?
| | Antigens, Surface | 1 | 2013 | 157 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2016 | 863 | 0.090 |
Why?
| | Coculture Techniques | 1 | 2013 | 246 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1887 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1782 | 0.090 |
Why?
| | Phylogeny | 1 | 2016 | 1016 | 0.090 |
Why?
| | Flow Cytometry | 1 | 2014 | 1173 | 0.080 |
Why?
| | Epitopes | 1 | 2013 | 485 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1462 | 0.080 |
Why?
| | Genome, Human | 1 | 2013 | 422 | 0.080 |
Why?
| | B7-2 Antigen | 1 | 2009 | 27 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2009 | 77 | 0.070 |
Why?
| | Lymphocytes | 1 | 2011 | 382 | 0.070 |
Why?
| | B7-1 Antigen | 1 | 2009 | 55 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2011 | 379 | 0.070 |
Why?
| | Listeriosis | 1 | 2009 | 65 | 0.070 |
Why?
| | Phosphorylation | 1 | 2013 | 1732 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 219 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 325 | 0.070 |
Why?
| | Neurons | 1 | 2016 | 1640 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2007 | 97 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2007 | 229 | 0.060 |
Why?
| | Integrin beta1 | 1 | 2026 | 33 | 0.060 |
Why?
| | Prognosis | 1 | 2014 | 4282 | 0.060 |
Why?
| | Proteinuria | 1 | 2026 | 102 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 766 | 0.060 |
Why?
| | Kidney Glomerulus | 1 | 2026 | 128 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 178 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 389 | 0.050 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2024 | 26 | 0.050 |
Why?
| | Doxorubicin | 1 | 2026 | 397 | 0.050 |
Why?
| | Disease Progression | 2 | 2022 | 2847 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2608 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2007 | 784 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 846 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 311 | 0.050 |
Why?
| | Male | 2 | 2026 | 72315 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.040 |
Why?
| | Female | 4 | 2026 | 78271 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 27 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1129 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 207 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2020 | 251 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2003 | 380 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2020 | 193 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 297 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 557 | 0.030 |
Why?
| | Cell Line | 2 | 2011 | 2882 | 0.030 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2011 | 2 | 0.020 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2011 | 10 | 0.020 |
Why?
| | Protein Structure, Quaternary | 1 | 2011 | 116 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 104 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 187 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2009 | 117 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2010 | 160 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 254 | 0.020 |
Why?
| | Listeria monocytogenes | 1 | 2009 | 116 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 194 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1329 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 688 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2009 | 264 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2010 | 420 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 851 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1217 | 0.010 |
Why?
| | Middle Aged | 1 | 2026 | 35875 | 0.010 |
Why?
| | Adult | 1 | 2026 | 40449 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4154 | 0.010 |
Why?
|
|
Zhu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|